DelveInsight has launched a new report on “Migraine-Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Migraine–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
The World Health Organization’s disability rating for migraine ranks it as the 19th most common reason for disability.
According to the Organization, it is ranked globally as the 7th most disabling disease among all diseases (responsible for 2.9% of all years of life lost to disability/YLDs) and the leading cause of disability among all neurological disorders.
According to the Foundation, it is an extraordinarily prevalent neurological disease. About 39 million people in the US and 1 billion people all over the globe are affected by migraine.
According to the Survey, 2018, women were nearly twice as likely as men to have had a severe headache or migraine in the past 3 months (20.1% versus 10.6%), both overall and within each age group. The percentage of persons experiencing severe headache or migraine declined with age for both men and women, from 25.5% among those aged 18–44 years to 7.6% among those aged ≥75 years for women and from 12.3% among those aged 18–44 years to 4.0% among those aged ≥75 years for men.
According to the Foundation, healthcare and lost productivity costs associated with migraine are estimated to be as high as USD 36 billion annually in the US.
Key benefits of the report:
1.The Migraine market report covers a descriptive overview and comprehensive insight of the Migraine epidemiology and Migraine market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2.The Migraine market report provides insights into the current and emerging therapies.
3.Migraine market report provides a global historical and forecasted market covering drug outreach in 7MM.
4.The Migraine market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Migraine market.
Request for sample pages: https://www.delveinsight.com/sample-request/migraine-market
Migraine: Overview
Migraine is a neurological condition that can cause many symptoms. It is often seen with a strong, depressing head. Symptoms may include nausea, vomiting, difficulty speaking, numbness or wheezing, and sensitivity to light and sound. Migraines often run in families and affect every year.
Diagnosis of migraine headaches is determined based on clinical history, reported symptoms, and determining other causes. The most common categories of migraine headaches are those without aura (formerly known as general migraines) and those with aura (formerly known as classic migraines).
Migraines can start in childhood or not occur into adulthood. Women are more likely to have migraines than men. Family history is one of the most common causes of migraines.
The key players involved in the Migraine market:
Axsome Therapeutics,
Impel NeuroPharma,
Zosano Pharma Corporation
The launch of the emerging therapies is expected to significantly impact the Migraine treatment scenario in the upcoming years:-
Drug covered
AXS-07
INP104
M207/ADAM Zolmitriptan
Request a free sample report @ https://www.delveinsight.com/sample-request/migraine-market
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Migraine Patient Share (%) Overview at a Glance
5. Migraine Market Overview at a Glance
6. Migraine Disease Background and Overview
7. Migraine Epidemiology and Patient Population
8. Country-Specific Patient Population of Migraine
9. Migraine Current Treatment and Medical Practices
10. Unmet Needs
11. Migraine Emerging Therapies
12. Migraine Market Outlook
13. Country-Wise Migraine Market Analysis (2017–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Migraine Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Migraine-Pipeline Insights, 2021
“Migraine-Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Migraine market. A detailed picture of the Migraine pipeline landscape is provided, which includes the disease overview and Migraine treatment guidelines.
Migraine-Epidemiology Forecast to 2030
DelveInsight’s ‘Migraine-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Non-small cell lung cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
